Crinetics Pharmaceuticals Quarter 2, 2025 Earnings Conference Discourse Transcript
Crinetics Pharmaceuticals Inc. (CRNX) has announced its Q2 2025 earnings, showing a revenue of $1.0 million, a net loss of $115.6 million, and cash reserves of $1.2 billion. The company's losses widened compared to the prior year due to increased investments in clinical development and commercial preparations for its lead drug candidate, PALSONIFY™ (paltusotine).
The earnings call, held on August 7, 2025, at 4:30 PM ET, was facilitated by an unnamed operator. Participants included key executives such as Alan S. Krasner, Dana Pizzuti, Gayathri Diwakar, Isabel Kalofonos, R. Scott Struthers, Stephen F. Betz, Tobin C. Schilke, and other unspecified individuals in various roles.
Isabel Kalofonos, the Chief Commercial Officer, and Tobin Schilke, the Chief Financial Officer, led the discussion, highlighting the company's strategic focus on advancing multiple endocrine disease programs while preparing for a commercial launch of PALSONIFY.
R&D expenses rose significantly to $80.3 million, reflecting expanded clinical trials and manufacturing efforts across multiple pipeline programs, including acromegaly, congenital adrenal hyperplasia (CAH), carcinoid syndrome, and neuroendocrine tumors. SG&A expenses increased to $49.8 million due to growth in personnel and commercial readiness activities ahead of PALSONIFY’s anticipated launch.
Operationally, Crinetics emphasized progress in the FDA review of PALSONIFY, with the crucial action date in late September 2025. The European Medicines Agency (EMA) has also accepted the marketing application for paltusotine, with a potential European decision in H1 2026.
Upcoming pivotal trials are planned in 2025 for atumelnant in CAH patients (Phase 2/3 pediatric) and adults (Phase 3), plus a Phase 1/2 solid tumor trial for CRN09682.
Dr. Steve Betz and Dr. Alan Krasner will join for the Q&A session. Gayathri Diwakar, the Head of Investor Relations, was also present. A slide deck is available for the presentation.
The conference call highlighted Crinetics’ strategic focus on balancing significant clinical investments against expected future revenues linked to drug approvals. With strong cash reserves and upcoming key regulatory milestones, the company is well-positioned for future growth.
[1] Crinetics Pharmaceuticals, Inc. Q2 2025 Earnings Conference Call Press Release. (2025). Retrieved from [https://www.crinetics.com/news-events/press-releases/detail/165/crinetics-pharmaceuticals-reports-second-quarter-2025]
[3] Crinetics Pharmaceuticals, Inc. Q2 2025 Earnings Conference Call Transcript. (2025). Retrieved from [https://seekingalpha.com/symbol/CRNX/transcripts/4505012-crinetics-pharmaceuticals-inc-crnx-q2-2025-earnings-call-transcript]
Investors might be interested to know that the company's focus on expanding clinical trials and commercial preparations for PALSONIFY resulted in increased R&D and SG&A expenses. Moving forward, the company aims to balance these investments with expected future revenues linked to drug approvals, such as the anticipated launch of PALSONIFY and key regulatory milestones in the FDA review and European Medicines Agency (EMA) decision.
